Literature DB >> 15780569

Prediction by quantitative histology of pathological stage in prostate cancer.

P Pepe1, A Galia, F Fraggetta, G Grasso, R Allegro, F Aragona.   

Abstract

AIMS: To find a predictor of extraprostatic extension in clinically localized prostate cancer (PCa), pre-operative ultrasound-guided prostate needle biopsies and clinico-pathological data were reviewed.
METHODS: One hundred and eighty-three consecutive patients who underwent radical retropubic prostatectomy for clinical T1-T2 PCa and serum PSA <10 ng/ml were reviewed. Pre-operative biopsy was performed according to an extended protocol and whole-mount prostatectomy specimens were processed. The following biopsy variables were categorized to this analysis: Gleason score (< or =6, >6), TPC (< or =20%; >20%), GPC (< or =50%; >50%), cancer-positive cores (< or =2; >2), cancer-positive cores in both lateral portions (yes; no), PCa (monolateral; bilateral).
RESULTS: Only 60/183 specimens showed an organ-confined PCa; the remaining ones showed pT3a in 57 cases, pT3b in 11 and pT3 with positive surgical margins in 55. A locally advanced PCa was found in 60.2 and 76.8% of T1c and T2 clinical stage, respectively. The positive predictive value and negative predictive value of biopsy findings to predict a locally advanced PCa was 89.9 and 75%, respectively. All biopsy variables associations were statistically significant; however, among these variables (non-categorized), in multivariate logistic regression analysis, only GPC was significantly associated with pathologic stage (odds ratio estimate was 1.075, 95% CI: 1.053-1.098).
CONCLUSIONS: Quantitative histology, especially GPC, seems to be helpful for pre-operative staging of PCa in patients with T1c-T2 clinical stage and PSA < 10 ng/ml.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15780569     DOI: 10.1016/j.ejso.2004.12.002

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  2 in total

Review 1.  Random biopsy: when, how many and where to take the cores?

Authors:  Vincenzo Scattoni; Carmen Maccagnano; Umberto Capitanio; Andrea Gallina; Alberto Briganti; Francesco Montorsi
Journal:  World J Urol       Date:  2014-06-08       Impact factor: 4.226

2.  Utilization of extended donor criteria liver allografts maximizes donor use and patient access to liver transplantation.

Authors:  John F Renz; Cindy Kin; Milan Kinkhabwala; Dominique Jan; Rhaghu Varadarajan; Michael Goldstein; Robert Brown; Jean C Emond
Journal:  Ann Surg       Date:  2005-10       Impact factor: 12.969

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.